Skip to main content
TipRanks
Go Ultimate75% OFF

Crescent Biopharma (C68) Q1 2024 Earnings Report

2 Followers

DE:C68 Q1 2024 EPS Results

Actual EPS
-EUR 15.42
Consensus EPS
-EUR 14.52
Beat/Miss
Missed by -EUR 0.91
One Year Ago EPS
-EUR 15.42

DE:C68 Q1 2024 Revenue Results

Actual Revenue
EUR 0
Expected Revenue
EUR 0
Beat/Miss
Met expectations
YoY Revenue Growth
―

Earnings Announcement Details

Quarter
Q1 2024
Date
05/06/2024
Time
Before Open
Conference Call
Monday, May 6, 2024
DE:C68 Upcoming Earnings

Crescent Biopharma's next earnings date is estimated for March 4, 2027, based on past reporting schedules.

Q1 2024 Earnings Call Audio

No earnings call audio is available for this earnings event.

Q1 2024 Earnings Slide Deck

No slide deck is available for this earnings event.

Q1 2024 Earnings Call Summary

Q1 2024
Earnings Call Date:May 06, 2024|% Change Since:-92.70%|
Earnings Call Sentiment|Neutral

The earnings call revealed challenges with the Phase III trial not meeting its primary endpoint, leading to financial and strategic reassessments. However, there is a commitment to further analyze the rich data collected and ongoing trials continue to explore the potential of uproleselan in AML treatment.

Company Guidance

During the Q1 2024 earnings call for GlycoMimetics, the management provided updates on the Phase III study of their lead drug candidate, uproleselan, which unfortunately did not achieve a statistically significant improvement in overall survival for patients with relapsed/refractory acute myeloid leukemia (AML). The trial involved 388 patients across 70 sites in 9 countries, with a median overall survival of 13 months for the uproleselan arm and 12.3 months for the placebo arm. Despite not meeting its primary endpoint, the study's unexpected control group survival rate of over one year is considered unprecedented in this setting. The company plans to conduct a comprehensive analysis of the data in collaboration with medical, statistical, and regulatory experts and intends to present findings at a future medical meeting. Additionally, GlycoMimetics highlighted ongoing studies, including a National Cancer Institute-sponsored Phase II/III trial, and mentioned efforts to manage cash burn and revise budget plans as they proceed with further analyses and discussions with the FDA.

  • Low Discontinuation RateThe study had a low discontinuation rate of 3%, indicating good patient retention and adherence to the trial protocol.
  • Rich Data Set for Future AnalysisThe study involved 388 patients with an unprecedented follow-up of over 3 years, providing a rich data set for further analysis and potential insights into AML treatment.
  • Commitment to Further ResearchDespite the trial's primary endpoint not being met, GlycoMimetics remains committed to exploring uproleselan's potential in AML and plans to conduct a rigorous analysis of the data.
  • Ongoing Trials and Future PlansThe National Cancer Institute is sponsoring an ongoing Phase II/III trial evaluating uproleselan in newly diagnosed older patients with AML, and results will be shared when available.

DE:C68 Earnings History

DE:C68 earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 04, 20272026 (Q4)-0.86--3.64――
Nov 12, 20262026 (Q3)-0.63-0.82-1.1529.13% (+0.34)
Jul 30, 20262026 (Q2)-0.67-0.67-4.4784.99% (+3.80)
Apr 29, 20262026 (Q1)-0.80-0.64-16.1796.07% (+15.53)
Feb 26, 20262025 (Q4)-2.24-3.64-7.2649.88% (+3.62)
Nov 06, 20252025 (Q3)-1.78-1.15-326.9499.65% (+325.79)
Jul 31, 20252025 (Q2)-1.51-4.47-14.268.51% (+9.73)
May 01, 20252025 (Q1)-0.05-0.05-0.1570.59% (+0.11)
Feb 27, 20252024 (Q4)-0.07-0.10-0.1320.00% (+0.03)
Nov 07, 20242024 (Q3)-0.10-0.14-0.13-8.57% (-0.01)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed